At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Donepezil in Normalizing Brain Activation Patterns in People Genetically at Risk for Alzheimer's Disease
In Brief
A Phase 1 clinical trial evaluating donepezil for Alzheimer's Disease. Completed, enrolled 41 participants across 1 site.
Detailed Summary
The purpose of the study is to examine patterns of brain activity in people who are at risk for memory problems (e.g., Alzheimer's disease or dementia)before and after the medication donepezil. Although genetic testing will be done, the results will not be shared with study participants. Once the genetic testing is completed subjects may continue to the second phase of the study. During this time they will be asked to take the medication donepezil (which is approved by the FDA for the treatment of Alzheimer's disease). Donepezil is not FDA approved for healthy volunteers and is therefore considered investigational in this study.
Study Details
Timeline
Interventions
donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.